ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 825
October 15, 1997

NEUROPROTECTIVE AGENTS

THIRD INTERNATIONAL CONFERENCE

Editors and Conference Chairs
WILLIAM SLIKKER, JR. AND BRUCE TREMBLY

CONTENTS

Preface. By THE EDITORS ................................................................. xi

Part I. Endogenous Neuroprotectants: Adenosine

Protective Mechanisms of Adenosine in Neurons and Glial Cells. By
PETER SCHUBERT, Tadanori Ogata, Cristina Marchini, Stefano
Ferroni, and Karl Rudolph .......................................................... 1

Modulation of Apoptosis by Adenosine in the Central Nervous System: a
Possible Role for the A3 Receptor. Pathophysiological Significance
and Therapeutic Implications for Neurodegenerative Disorders. By
Maria P. Abracchio, Stefania Ceruti, Roberta Brambilla,
Claudio Franceschi, Walter Malorni, Kenneth A. Jacobson,
Dag K. J. E. von Lubitz, and Flaminio Cattabeni .......................... 11

Adenosine A1 Receptor Agonists as Clinically Viable Agents for
Treatment of Ischemic Brain Disorders. By Norbert Bischofberger,
Kenneth A. Jacobson, and Dag K. J. E. von Lubitz .......................... 23

Adenosine A2A Receptors and Neuroprotection. By Ennio Ongini,
Marina Adami, Cinzia Ferri, and Rosalia Bertorelli ......................... 30

Adenosine A3 Receptor and Brain: a Culprit, a Hero, or Merely Yet
Another Receptor? By Dag K. J. E. von Lubitz .............................. 49

Questions and Answers ............................................................... 68

Part II. Endogenous Neuroprotectants: Melatonin

Prophylactic Actions of Melatonin in Oxidative Neurotoxicity. By Rusel
J. Reiter, Juan M. Guerrero, Germaine Escames, Miguel A.
Pappolla, and Dario Acuña-Castroviejo ........................................ 70

* This volume contains the papers from a conference entitled Third International Conference
on Neuroprotective Agents: Clinical and Experimental Aspects, which was held at Lake Como,
Italy on September 9–12, 1996.
In Vitro and In Vivo Protective Effects of Melatonin against Glutamate Oxidative Stress and Neurotoxicity. By Pietro Giusti, Maria Lipartiti, Milena Gusella, Maura Floreani, and Hari Manev ............................................. 79

Neuroprotective Action of the Pineal Hormone Melatonin against Excitotoxicity: Receptor Abuse-Dependent Antagonism (RADA). By Hari Manev, Tolga Uz, and Pietro Giusti ................................................................. 85

Questions and Answers ............................................................. 90

Part III. Calpain and Neuronal Degeneration

Calcium-Activated Proteolysis as a Therapeutic Target in Cerebrovascular Disease. By Kevin S. Lee, Hiroji Yanamoto, Andrea Fergus, Seung-Chyul Hong, Sung-Don Kang, Barbara Cappelletto, Tomikatsu Toyoda, Neal F. Kassell, Murad Bavbek, and Ali-Lie Kwan ................................................................. 95


Calpain, a Mediator of Myelin Breakdown in Demyelinating Diseases. By Donald C. Shields, Gladys E. Deibler, and Naren L. Banik ................................................................. 128

Questions and Answers ............................................................. 131

Part IV. Mechanisms and Modulation of Neurodegeneration

The Role of Dendritic Dysfunction in Neurodegeneration. By Rick C. S. Lin, Diane F. Matesic, and John A. Connor ................................................................. 134

Compensatory Long-Term Effect of Perinatal Hypoxia-Ischemia: a Possible Mechanism for Neuroprotection? By Zbigniew Binenda ................................................................. 146

Toxin-Induced Blood Vessel Inclusions Caused by the Chronic Administration of Aluminum and Sodium Fluoride and Their Implications for Dementia. By Robert L. Isaacson, Julie A. Varner, and Karl F. Jensen ................................................................. 152

Role of Heat Shock Proteins in MPTP-Induced Neurotoxicity. By Tim E. Freyaldenhoven and Syed F. Ali ................................................................. 167

Inflammatory Gene Expression in Cerebral Ischemia and Trauma: Potential New Therapeutic Targets. By Giora Z. Feuerstein, Xinkang Wang, and Frank C. Barone ................................................................. 179

Excitotoxic Mechanisms of Neurodegeneration in Transmissible Spongiform Encephalopathies. By Andrew C. Scallet and Xuemin Ye ................................................................. 194

Questions and Answers ............................................................. 206
## Part V. NMDA Antagonists


Low-Affinity NMDA Receptor Antagonists: the Neuroprotective Potential of ARL 15896AR. *By* Gene C. Palmer, Jerry A. Miller, Edward F. Cregan, Patricia Gendron, and James Peeling ............ 220

Neuroprotective Effects of Eliprodil in a Rat Hippocampal Slice Hypoxia Model. *By* R. Santamaría, D. Françon, H. Depoortere, and B. Scatton ........................................... 232

Questions and Answers ........................................... 239

## Part VI. Cellular and Neuronal Environmental Manipulation in Neuroprotection


Effect of Selective Brain Cooling during Cerebral Ischemia on Postischemic Brain Water Content in Rabbit. *By* Kyu Taek Choi, Jeong Kil Leem, Dong Myung Lee, and Byung Te Suh .......... 258

An Advanced *In Vitro* Model to Study Hypoxia/Low Glucose-Induced Neuronal Cell Damage and Death. *By* M. P. Tabor, H. B. van der Worp, P. Sadoor, H. Veldman, E. A. J. Joosten, G. Strous, and P. R. Bär ........................................... 267

Questions and Answers ........................................... 279

## Part VII. Clinical Aspects of Neuroprotection


Subclinical Neurological and Neurovascular Deficits in Cocaine Dependence: Gender and Psychosocial Considerations. *By* Deborah E. King, Ronald I. Herning, and Jean L. Cadet .................. 328

Questions and Answers ........................................... 332
Part VIII. Newer Agents as Potential Neuroprotectants

Astrocyte Metallothioneins (MTs) and Their Neuroprotective Role. By
MICHAEL ASCHNER ................................................................. 334

Neuregulins as Potential Neuroprotective Agents. By MARK A.
MARCHIONNI, JUDITH B. GRINSSPAN, PETER D. CANOLL, NAGESH K.
MAHANTHAPPA, JAMES L. SALZER, AND STEVEN S. SCHERER .......... 348

Poly(ADP-Ribose) Polymerase (PARP) Revisited. A New Role for an
Old Enzyme: PARP Involvement in Neurodegeneration and PARP
Inhibitors as Possible Neuroprotective Agents. By C. COSI, H.
SUZUKI, S. D. SKAPER, D. MILANI, L. FACCI, M. MENEGAZZI, G.
VANTINI, Y. KANAI, A. DEGRYSE, F. COLPAERT, W. KOEK, AND
M. R. MARIEN. ................................................................. 366

Ion Channels as Targets for Neuroprotective Agents. By TOSHIO
NARASHASHI, CHAO-SHENG HUANG, JIN-HO SONG, AND JAY Z. YEH ... 380

Is Low Molecular Weight Heparin a Neuroprotectant? By SARAN JONAS,
MUTSUYUKI SUGIMORI, AND RODOLFO LLINÁS .......................... 389

Pharmacology of the AMPA Antagonist 2,3-Dihydroxy-6-Nitro-7-
Sulfamoylbenzo-(F)-Quinoxaline. By CHRYSANTHY IKONOMIDOU AND
LECHOSLAW TURSKI .......................................................... 394

Questions and Answers ........................................................ 403

Part IX. Regulatory Issues

Current and Future Approaches to Neurotoxicity Risk Assessment. By
WILLIAM SLIKKER, JR. AND THOMAS J. SOBOTKA ......................... 406

General Questions and Answers .............................................. 419

Part X. Conference Survey

Summary of Survey Results from the Third International Conference on
Neuroprotective Agents. By WILLIAM SLIKKER, JR. AND BRUCE
TREMBLY ........................................................... 428

Subject Index ........................................................................ 431

Index of Contributors .......................................................... 437